Bioethics News

The Unbearably Slow Adoption of Genetic Cancer Tests

July 14, 2016

(The Atlantic) – In the world of cancer medicine, bureaucracy can be as difficult an adversary as tumors. And sometimes, the biggest wins aren’t in making splashy, technology-driven scientific discoveries, but in doing the thankless, unglamorous logistical work that allows patients to actually benefit from said discoveries. “It’s about making sure that the things we’ve done are genuinely going to help people,” says Rahman. Every year, 225,000 women around the world are diagnosed with ovarian cancer, and between 10 and 15 percent of these cases are driven by inherited mutations in two genes, BRCA1 and BRCA2. It’s important for women to know if they’re part of that 15 percent; their health, and that of their relatives, might depend on it.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.